Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, was approved by the FDA (The U.S. Food and Drug Administration) to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.
The FDA granted Priority Review and orphan drug designations for Onivyde. Priority review status is granted to applications for drugs that, if approved, would be a significant improvement in safety or effectiveness in the treatment of a serious condition.
Read more about this approval here.
#PancreaticCancerAwarenessMonth #pancreaticcancer #cancerresearch #fda #fdaapproval #onivyde #advancedpancreaticcancer #metastaticpancreaticcancer